Abbott Laboratories (ABT)
NYSE • Healthcare
October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Abbott Laboratories keeps $7 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 21
in 18 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Abbott Laboratories' adjusted EPS topped consensus while revenue came in line in the second fiscal quarter of 2026, reported July 16, as revenue rose 13% to about $12.6 billion and gross margin held near 58% while operating margin was around 14%. Adjusted EPS of $1.31 topped the $1.28 estimate, +2.3%, and revenue of $12.593 billion was in line with the $12.519 billion consensus, +0.6%; net income fell 47.8% to about $928 million from $1.779 billion a year ago, even as adjusted EPS rose 4% from $1.26. Operating cash flow was $2.488 billion, the company repurchased about $1.0 billion of stock and paid about $1.1 billion in dividends. Next-period consensus calls for EPS of $1.42 on revenue of $12.991 billion.
Next report — what to expect
Abbott Laboratories (ABT) is scheduled to report earnings on October 21, 2026. Wall Street’s next-period consensus calls for EPS of $1.43 on revenue of $12.99 billion. As trailing context, revenue grew +13.0% year over year last quarter. Abbott has beaten EPS in 4 of 8 most recent quarters.
About Abbott Laboratories
Abbott Laboratories (NYSE: ABT) is a healthcare company centered on medical devices, diagnostics, nutrition, and branded generic medications sold through worldwide distribution, with operations that reach global markets. Across these businesses, Abbott generated $44.3 billion of revenue in FY2025, spanning products used in testing, chronic disease management, and everyday nutritional care.
Today's Snapshot
The day ended with ABT 0.8% higher at 97.50, while its sector was flat. Rothschild & Co Redburn, an analyst firm, upgraded Abbott to Buy and raised its price target to $127.
Trading Volume
Below 10d avg (7.7M)
6.5M
vs S&P 500 Today
Inline with Market
+0.06%
Updated: October 2, 2026 at 20:04 UTC
ABT Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$100.15 - $108.23Sell
- RSI (14)29.69Buy
- Stochastic %K (14, 3, 3)9.83Buy
- MACD Level (12, 26)-2.37Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.